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Inhibition of nociception through activation of peripheral
μ opioid receptors (MOR) avoiding the central adverse
effects of opioids has added a new possibility to manage
pain control. Here we report the antinociceptive effects of
the peripherally restricted MOR agonist HS-731, the pep-
tide DAMGO, and morphine in the writhing test in mice.
S.c. and i.c.v. HS-731 dose-dependently and completely
inhibited writhing, being 24–598 times more potent than
the two MOR-selective agonists DAMGO and morphine.
However, extremely high s.c./i.c.v. potency ratios were cal-
culated for HS-731 and DAMGO and much lower for
morphine. Remarkably, a long duration of action was
induced by HS-731 and much shorter by morphine and
DAMGO. The antinociceptive effects of systemic opioids
were reversed by s.c. naloxone while i.c.v. administration
of the MOR selective antagonist CTAP significantly abol-
ished the antinociceptive effect of s.c. morphine but com-
pletely failed to antagonize the effects of systemic HS-731
or DAMGO. In addition, in the rat vas deferens HS-731
and DAMGO, but not morphine, showed high intrinsic
efficacy and naltrexone-sensitive agonist response at MOR
by depressing electrically-evoked contractions of this
organ. These data demonstrate that the selectivity and
high efficacy of HS-731 and DAMGO at peripheral MOR
as well as their inability to cross the blood brain barrier
are a cornerstone for producing peripheral antinocicep-
tion after systemic administration.
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